Secondary Leukemia and Myelodysplastic Syndrome in Children with Acute Lymphocytic Leukemia and Non-Hodgkin's Lymphoma Treated with TCCSG Protocol.
スポンサーリンク
概要
- 論文の詳細を見る
We investigated the occurrence of secondary acute myelocytic leukemia (AML) or myelodysplastic syndrome (MDS) in children with acute lymphocytic leukemia (ALL) and non-Hodgkin's lymphoma (NHL) treated with TCCSG protocol. a) ALL : Secondary AML or MDS developed in seven of 1, 209 ALL patients (cumulative risk at seven years, 1.5%). The median time from the initiation of chemotherapy to the development of secondary AML or MDS was 42 months (range, 18 to 79). Four patients developed AML and 3 developed MDS. b) NHL : Secondary AML developed in eight of 38 NHL patients treated with T-8801 (cumulative risk at 70 months, 27.6%). The median time from initiation of chemotherapy to the development of secondary AML or MDS was 29 months (range, 13 to 66). There were no secondary AML patients among the 50 NHL patients treated with other T-NHL protocols or among the 101 NHL patients treated with B-8801 or B-9201. Secondary AML and MDS were resistant to chemotherapy and showed poor prognosis. Chromosomal translocations involving 11q23 were demonstrated in five of 15 patients with secondary AML or MDS.
- 特定非営利活動法人 日本小児血液・がん学会の論文
特定非営利活動法人 日本小児血液・がん学会 | 論文
- The Parent's Emotional Adaptation to the Children's Malignant Disease
- Side Effect of Cranial Radiation in Childhood Acute Leukemia
- Red Blood Cell Volume Distribution Width in Normal Children and in the Patients with Various Kinds of Hematological Disorders.
- Effective Conditioning of Donors for Granulocyte Transfusions with Recombinant Human Granulocyte Colony-Stimulating Factor.
- Two Infant Girls of CNS Leukemia with Chronic Subdural Hematoma